imidapril and Lupus-Nephritis

imidapril has been researched along with Lupus-Nephritis* in 1 studies

Other Studies

1 other study(ies) available for imidapril and Lupus-Nephritis

ArticleYear
Effect of combining ACE inhibitor and statin in lupus-prone mice.
    Clinical immunology (Orlando, Fla.), 2010, Volume: 136, Issue:2

    MRL-Fas(lpr) mice spontaneously develop a systemic autoimmune disease resembling human systemic lupus erythematosus. The glomerulonephritis in MRL-Fas(lpr) mice is mediated by autoantibodies and autoreactive lymphocytes. To investigate the effect of combination therapy by angiotensin-converting enzyme inhibitor (ACEI) and hydroxymethylglutaryl-coenzyme A reductase inhibitor (statin) for lupus nephritis, we treated MRL-Fas(lpr) mice with imidapril, pravastatin or both agents. Compared with other groups, the mice treated by combination therapy survived longer and showed a significant reduction in proteinuria, renal pathology, including glomerular IgG deposit, and serum anti-DNA Ab. Furthermore, monocyte chemoattractant protein-1 (MCP-1) in the kidney was reduced significantly in the combination therapy group, compared with that in the control group. We conclude that combination therapy with ACEI and statin for MRL-Fas(lpr) mice significantly alleviates autoimmune renal disorder and prolongs survival. These results suggest that combination therapy by ACEI and statin may represent a new approach to the treatment of patients with lupus.

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antibodies, Antinuclear; Blood Pressure; Cytokines; Drug Therapy, Combination; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazolidines; Immunoglobulin G; Kidney; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Mice, Inbred C3H; Mice, Inbred MRL lpr; Pravastatin; Proteinuria; Random Allocation; Specific Pathogen-Free Organisms

2010
chemdatabank.com